1. Home
  2. CSAI vs IKT Comparison

CSAI vs IKT Comparison

Compare CSAI & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CSAI
  • IKT
  • Stock Information
  • Founded
  • CSAI N/A
  • IKT 2008
  • Country
  • CSAI
  • IKT United States
  • Employees
  • CSAI N/A
  • IKT N/A
  • Industry
  • CSAI
  • IKT Biotechnology: Pharmaceutical Preparations
  • Sector
  • CSAI
  • IKT Health Care
  • Exchange
  • CSAI NYSE
  • IKT Nasdaq
  • Market Cap
  • CSAI N/A
  • IKT 167.2M
  • IPO Year
  • CSAI N/A
  • IKT 2020
  • Fundamental
  • Price
  • CSAI $4.92
  • IKT $2.29
  • Analyst Decision
  • CSAI
  • IKT Buy
  • Analyst Count
  • CSAI 0
  • IKT 2
  • Target Price
  • CSAI N/A
  • IKT $8.00
  • AVG Volume (30 Days)
  • CSAI N/A
  • IKT 126.8K
  • Earning Date
  • CSAI N/A
  • IKT 05-14-2025
  • Dividend Yield
  • CSAI N/A
  • IKT N/A
  • EPS Growth
  • CSAI N/A
  • IKT N/A
  • EPS
  • CSAI N/A
  • IKT N/A
  • Revenue
  • CSAI N/A
  • IKT N/A
  • Revenue This Year
  • CSAI N/A
  • IKT N/A
  • Revenue Next Year
  • CSAI N/A
  • IKT N/A
  • P/E Ratio
  • CSAI N/A
  • IKT N/A
  • Revenue Growth
  • CSAI N/A
  • IKT N/A
  • 52 Week Low
  • CSAI N/A
  • IKT $1.12
  • 52 Week High
  • CSAI N/A
  • IKT $4.20
  • Technical
  • Relative Strength Index (RSI)
  • CSAI N/A
  • IKT 46.39
  • Support Level
  • CSAI N/A
  • IKT $2.08
  • Resistance Level
  • CSAI N/A
  • IKT $2.46
  • Average True Range (ATR)
  • CSAI 0.00
  • IKT 0.16
  • MACD
  • CSAI 0.00
  • IKT 0.02
  • Stochastic Oscillator
  • CSAI 0.00
  • IKT 54.69

About IKT Inhibikase Therapeutics Inc.

Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.

Share on Social Networks: